Dragana Bugarski-Kirola, MD, MBA, MSc

ENHANCE Trial: Adherence to Current Antipsychotic and Adjunctive Pimavanserin in Patients With Schizophrenia and Inadequate Response to Antipsychotic Treatment

Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...

Brandon Abbs , PhD;

Mona Darwish , PhD;

Dragana Bugarski-Kirola , MD, MBA, MSc;

Yuan Liu , MSc;

Srdjan Stankovic , MD, MSPH;

10/27/2020

Safety Profile of Adjunctive Pimavanserin in the ENHANCE Study, a Phase 3 Trial for the Potential Treatment of Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment

Many patients with schizophrenia do not respond fully to antipsychotic treatment despite adherence. Evidence supporting polypharmacy is limited and adding another antipsychotic is associa...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

I-Yuan Liu , MSc;

Rene Nunez , MD;

Ramzey Odetalla , PA, MSc;

Mohammed Bari , MD;

Istvan Bitter , MD, PhD, DSc;

Peter Feldman , PhD;

10/08/2020

ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia

Pimavanserin is a selective, 5-hydroxytryptamine (5-HT)2A receptor inverse agonist/antagonist with lower activity at 5-HT2C receptors. Previous studies have shown beneficial effects of ad...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

Celso Arango , MD, PhD;

Henry Nasrallah , MD;

I-Yuan Liu , MSc;

Brandon Abbs , PhD;

Maurizio Fava , MD, PhD;

10/08/2020